Trial · NCT02477826
Adverse events6,540
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 6,540
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Part 1-Arm B: Nivo + Ipi | 47 | 391 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 1-Arm A: Nivolumab | 51 | 391 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 1-Arm C: Chemotherapy | 159 | 387 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 1-Arm D: Nivo + Ipi | 25 | 185 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 1-Arm G: Nivo + Chemo | 80 | 172 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 1-Arm F: Chemotherapy | 76 | 183 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 2 - Arm H: Nivolumab + Chemotherapy | 174 | 375 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 2 - Arm I: Chemotherapy | 151 | 371 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 3 -Arm J: Nivolumab + Ipilimumab | 63 | 126 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 3 - Arm K: Chemotherapy | 93 | 123 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Part 1-Arm B: Nivo + Ipi | 6 | 391 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Part 1-Arm A: Nivolumab | 4 | 391 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Part 1-Arm C: Chemotherapy | 1 | 387 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Part 1-Arm D: Nivo + Ipi | 4 | 185 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Part 1-Arm G: Nivo + Chemo | 1 | 172 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Part 1-Arm F: Chemotherapy | 1 | 183 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Part 2 - Arm H: Nivolumab + Chemotherapy | 4 | 375 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Part 2 - Arm I: Chemotherapy | 4 | 371 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Part 3 -Arm J: Nivolumab + Ipilimumab | 9 | 126 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Part 3 - Arm K: Chemotherapy | 4 | 123 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02477826/events